Skip to main content
Nocira logo

Nocira

Tempe, ArizonaFounded 2017

  • Neuromodulation
  • Series B
  • Migraine

Nocira is a medical technology company developing an investigational, non-invasive device system for acute migraine treatment. Its approach uses controlled air-pressure changes in the ear to stimulate sensory nerves and influence pain-processing centers in the brain.

Raised
$9.5M
Jun 2017
Series B
Investor
1
Founded
2017
Employees
1–10

reccy insights

Recent highlights

Nocira’s identifiable milestones center on its migraine-treatment technology rather than a steady stream of corporate announcements. The company raised a $9.5 million Series B on Jun 12, 2017, with AZ Crown Investments as lead investor. Subsequent patent activity points to continued work on its ear-based pressure approach: an external ear canal pressure regulation device was documented in 2021, an ear-pump patent in 2022, and filings concerning a magnetically driven pressure generator and pressure adjustment devices appeared in 2023 and 2024. These developments align with Nocira’s described investigational system, which delivers controlled air-pressure pulses into the ear and is paired with a mobile application. A Aug 25, 2026 headline about Avulux migraine lenses is not a Nocira milestone and is excluded.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Nocira distinct

  1. 01Developing a non-invasive alternative to medication and injections for acute migraine treatment.
  2. 02Uses controlled air-pressure changes in the ear to stimulate sensory nerve pathways.
  3. 03Pairs the investigational treatment device with a mobile platform for device control and therapy tracking.
  4. 04Designed to offer a treatment experience that may avoid medication-related side effects; clinical benefits are not established here.

Technology & products3

  • Investigational Migraine Treatment Device

    A non-invasive medical device designed to treat migraines by delivering modulated air-pressure pulses into the ear to stimulate pressure-activated sensory neurons.

  • Mobile App for Device Control

    A mobile application that controls the migraine treatment device, allowing users to enter migraine information and monitor therapy progress.

  • Clinical Trial

    A double-blinded, randomized, placebo-controlled, multi-center clinical trial intended to evaluate the device’s clinical effectiveness and safety.

Funding

$9.5M disclosed
  • Series BJun 2017
    $9.5MLed by AZ Crown Investments
1 investor

Similar companies

About Nocira

Products
Investigational Migraine Treatment Device, Mobile App for Device Control, Clinical Trial
Leadership
Jim Peacock, CEODavid George, Co-Founder, Chief Scientific Officer, and VP of Product DevelopmentTim Crown, Chairman of the Board and Co-FounderHarshal Deshpande, Chief Commercial Officer
Focus areas
NeuroTechnology, medical devices, digital health, clinical research, therapeutics, migraine, neuromodulation, neurology
Headquarters
Tempe, Arizona
Founded
2017
Employees
1–10
Patents granted
20
Trademarks
1